Ninte acts as a "triple angiokinase inhibitor," targeting three main receptor families involved in the signaling pathways of fibrosis and tumor growth:
Beyond lung disease, Ninte is being investigated for its potential to treat other forms of fibrosis and cancer: ResearchGate
By blocking these receptors, Ninte inhibits the processes that lead to excessive scarring and tissue stiffening. Primary Clinical Uses Ninte is primarily prescribed for the following conditions: Ninte acts as a "triple angiokinase inhibitor," targeting
: These play a role in blood vessel formation (angiogenesis).
: It is used for various interstitial lung diseases that continue to worsen despite treatment. Emerging Research and Oncology Emerging Research and Oncology : These are critical
: These are critical for fibroblast proliferation. Platelet-Derived Growth Factor (PDGFR) : These drive the activation and survival of fibroblasts.
: It is one of only two approved drugs (the other being pirfenidone) proven to slow the annual rate of lung function decline by approximately 50%. (often abbreviated as Ninte ) is a potent,
(often abbreviated as Ninte ) is a potent, oral, small-molecule tyrosine kinase inhibitor primarily used as an anti-fibrotic medication. Developed by Boehringer Ingelheim and approved by the FDA in 2014, it has become a standard of care for several progressive lung diseases. Mechanism of Action